Company Overview
| Stock Name | Golden Throat |
|---|---|
| Stock Code | 06896 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是中國領先的潤喉片製造商,旗艦產品金嗓子喉片於1994年推出,另產銷銀杏葉片、金銀三七膠囊及複方百部止咳顆粒等藥品,以及金嗓子喉寶系列食品。 |
| Listing Date | 2015-07-15 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 廣西壯族自治區柳州市躍進路28號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | goldenthroat.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 4.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | 500 shares |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2015-06-30 to 2015-07-06 |
| Global Offering Shares | 181,590,000 shares |
| HK Public Offer Shares (Initial) | 18,159,000 shares (10.0%) |
| Public Offer Lots (Initial) | 36,318lots (Pool A18,159lots,Pool B18,159lots) |
| International Placing Shares (Initial) | 163,431,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 726,360,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 9.3% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 835,314,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 2.07B |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +369% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣121.7百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Revenue | 587,802 | 548,857 | 606,801 |
| Cost of sales | -210,185 | -181,994 | -176,893 |
| Gross profit | 377,617 | 366,863 | 429,908 |
| Other income and gains, net | 14,668 | 15,766 | 18,250 |
| Selling and distribution expenses | -200,258 | -230,110 | -213,286 |
| Administrative expenses | -53,470 | -47,674 | -59,101 |
| Operating profit | 136,474 | 97,969 | 170,376 |
| Net finance costs | -7,972 | -5,726 | -13,538 |
| Profit before tax | 128,502 | 92,243 | 156,838 |
| Income tax expense | -25,658 | -22,325 | -35,128 |
| Profit for the year | 102,844 | 69,918 | 121,710 |
| Profit attributable to owners | 102,844 | 69,918 | 121,893 |
Balance Sheet
| Item | 2012 | 2013 | 2014 |
|---|---|---|---|
| Cash and cash equivalents | 105,702 | 145,505 | 127,163 |
| Trade and bills receivables | 296,705 | 300,996 | 261,998 |
| Inventories | 85,790 | 48,319 | 47,853 |
| Total current assets | 576,185 | 509,608 | 495,866 |
| Total assets | 645,418 | 590,726 | 568,026 |
| Total current liabilities | 206,811 | 419,477 | 471,997 |
| Total liabilities | 211,087 | 423,713 | 476,674 |
| Total equity | 434,331 | 167,013 | 91,352 |
| Equity attributable to owners | 434,331 | 167,013 | 91,352 |
Income Statement
Balance Sheet
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 4.87 |
|---|---|
| First Day Open | HK$ 4.71 |
| First Day Change | 5.87% |
| First Day Volume | 22025000.0 |
| First Day Turnover | 107332000.0 |
| Use of Proceeds | 1、約23%(或175.9百萬港元)將用于興建位于廣西壯族自治區柳州市洛維工業集中區或替代土地的新藥品生產及研發基地;
2、約21%(或160.6百萬港元)將用于將我們現時位于廣西壯族自治區柳州市躍進路28號的總部改造成食品生產廠房及食品研發中心;
3、約32%(或244.7百萬港元)將用于2015年、2016年及2017年的市場擴展;
4、約9%(或68.8百萬港元)將用于產品開發;
5、約4%(或30.6百萬港元)將用于在我們現時位于廣西壯族自治區來賓市的場地建立中草藥加工基地;
6、約1%(或7.6百萬港元)將用于改進及升級我們的電子追蹤碼系統以更好地監控我們藥品及食品的分銷;
7、余下約10%的款項(或76.5百萬港元)將用作我們的營運資金及其他一般公司用途。 |
Underwriting Syndicate
Sole Sponsor (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Overall Coordinators (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Joint Lead Managers (1)
Credit Suisse (Hong Kong) Limited CE AAO017
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Super Silverwood Limited | 155,999,800 HKD | — | 4.70% | — | 6 months | 2016-01-15 |
| 2 | 广州润钿营销策划有限公司 | 77,999,900 HKD | — | 2.30% | — | 6 months | 2016-01-15 |
| 3 | 康健企业咨询及投资有限公司 | 46,798,100 HKD | — | 1.40% | — | 6 months | 2016-01-15 |
| 4 | 中国新锐医药控股有限公司 | 31,199,500 HKD | — | 0.90% | — | 6 months | 2016-01-15 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 江佩珍 | — |
| Company Secretary | 吳詠珊 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 曾勇先生透過家族信託、僱員信託及高級管理層信託控制緊接全球發售前全部已發行股本,緊隨全球發售後被視為持有已發行股本約75.0%;家族信託持有448,516,800股,佔約61.7%;江佩珍女士被視為持有96,253,200股,佔約13.3%。 |
|---|




